TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Clinical safety rating: avoid
Corticosteroids may increase edema risk and anticoagulants may have increased effects Can cause polycythemia and increased risk of cardiovascular events.
Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.
| Metabolism | Testosterone cypionate: Hydrolyzed to testosterone then metabolized primarily in the liver via oxidation (CYP3A4, CYP2C9) and conjugation; estradiol cypionate: Hydrolyzed to estradiol then metabolized via hydroxylation (CYP1A2, CYP3A4) and glucuronidation. |
| Excretion | Renal (90% as glucuronide and sulfate conjugates, less than 5% as unchanged drug); fecal (approximately 10%). |
| Half-life | Testosterone cypionate: approximately 8 days; estradiol cypionate: approximately 8-10 days. Clinical context: steady-state reached in 3-5 weeks. |
| Protein binding | Testosterone: 97-99% bound to sex hormone-binding globulin (SHBG) and albumin; estradiol: 98% bound to SHBG and albumin. |
| Volume of Distribution | Testosterone: approximately 0.6 L/kg; estradiol: approximately 0.5 L/kg. Indicates distribution into peripheral tissues. |
| Bioavailability | Intramuscular: approximately 100% due to slow release from oil depot; no oral bioavailability (hepatic first-pass inactivation). |
| Onset of Action | Intramuscular injection: therapeutic effects (e.g., libido, hot flash relief) noted within 1-2 weeks. |
| Duration of Action | Intramuscular injection: 2-4 weeks. Clinical note: dosing interval typically every 4 weeks due to prolonged release. |
| Molecular Weight | Testosterone cypionate: 412.58 Da; Estradiol cypionate: 396.56 Da |
Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended; use with caution in severe impairment due to limited data. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh C). For mild to moderate (Child-Pugh A or B), use with caution and monitor hepatic function. |
| Pediatric use | Not recommended for pediatric use; safety and efficacy not established. |
| Geriatric use | Use lower end of dosing range (e.g., testosterone cypionate 50-100 mg with estradiol cypionate 2-5 mg every 4 weeks) due to increased risk of cardiovascular and prostate adverse effects; monitor closely. |
| 1st trimester | Contraindicated. Androgens can cause virilization of female fetus; estradiol may increase risk of congenital anomalies. |
| 2nd trimester | Contraindicated. Risk of fetal harm, including ambiguous genitalia in female fetuses. |
| 3rd trimester | Contraindicated. Potential for adverse effects on fetal development and risk of premature closure of epiphyses. |
Clinical note
Corticosteroids may increase edema risk and anticoagulants may have increased effects Can cause polycythemia and increased risk of cardiovascular events.
| FDA category | Contraindicated |
| Placental transfer | Both testosterone and estradiol cross the placenta. Testosterone can be converted to dihydrotestosterone; estradiol can affect fetal development. |
| Breastfeeding |
■ FDA Black Box Warning
Estrogens, with or without progestins, should not be used for the prevention of cardiovascular disease or dementia. Increased risks of endometrial cancer, stroke, and deep vein thrombosis. Venous thromboembolism risk is increased with estrogen-containing products.
| Common Effects | Acne |
| Serious Effects |
Pregnancy or suspected pregnancyBreastfeedingKnown or suspected breast cancer (male or female)Active thromboembolic disordersSevere hepatic dysfunctionHypersensitivity to components
| Precautions | Cardiovascular risk: increased risk of myocardial infarction, stroke, venous thromboembolism, Endometrial cancer: unopposed estrogen use increases risk, Breast cancer: caution in patients with known or suspected estrogen-dependent tumors, Hepatic impairment: dose adjustment may be needed, Hypercalcemia: caution in patients with bone metastases, Fluid retention: caution in cardiac or renal dysfunction |
Loading safety data…
| Excreted in breast milk. Potential for androgenization of female infants and estrogenic effects. Avoid breastfeeding during therapy. |
| Lactation Rating | L5 – Contraindicated |
| Teratogenic Risk | First trimester: High risk of masculinization of female fetus. Second trimester: Androgenic effects may cause clitoral enlargement, labial fusion, and urogenital sinus abnormalities. Third trimester: Possible advanced bone age and growth acceleration. Not recommended in any trimester. |
| Fetal Monitoring | Monitor maternal blood pressure, signs of hypercalcemia, hepatic function, lipid profile, and blood glucose. Fetal ultrasound for signs of sexual ambiguity or growth abnormalities. |
| Fertility Effects | May suppress ovulation and impair fertility in women. In men, high doses may suppress spermatogenesis. Discontinuation may restore fertility. |
| Food/Dietary |
| Avoid excessive grapefruit juice as it may affect hormone metabolism. No specific food interactions; maintain a balanced diet. |
| Clinical Pearls | Monitor for signs of thromboembolism, especially in patients with risk factors. Measure serum testosterone and estradiol levels periodically to maintain therapeutic range. Use with caution in patients with history of myocardial infarction or stroke. Contraindicated in men with breast or prostate cancer. May cause gynecomastia and fluid retention. |
| Patient Advice | Report any signs of blood clots (leg pain, chest pain, shortness of breath) immediately. · Do not use if you are pregnant or breastfeeding. · Regular blood tests are required to monitor hormone levels and liver function. · Use as prescribed; do not adjust dose without consulting your healthcare provider. · Inform your doctor about all medications you are taking, including over-the-counter drugs. |